Fig. 2

Receiver operating characteristic curve of serum biomarkers. The curve showed ability of mesothelin, midkine or the combination to differentiate between malignant mesothelioma and a metastatic cancers to pleura, b benign asbestos pleurisy, c benign pleural disease or d pleural diseases other than mesothelioma that include metastatic cancers, benign asbestos pleurisy and benign pleural diseases